Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Froedtert and the Medical College of Wisconsin, Milwaukee, WI, USA.
Am J Health Syst Pharm. 2022 Jul 8;79(14):1137-1145. doi: 10.1093/ajhp/zxac091.
The pharmacology, efficacy, safety, and dosing/administration of new and emerging therapies for the treatment of multiple myeloma are summarized.
There have been significant advancements in the treatment of multiple myeloma in recent years, with an expansion of available drug therapies. Newer therapies for multiple myeloma include the anti-CD38 monoclonal antibodies daratumumab and isatuximab, the exportin 1 inhibitor selinexor, the anti-B-cell maturation antigen (BCMA) antibody-drug conjugate belantamab mafodotin, and the chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel. These agents have unique toxicity profiles, specific monitoring parameters, and operational considerations that clinicians treating multiple myeloma should be aware of. There is likely to be continued rapid expansion of new agents for patients with multiple myeloma, as there are many novel investigational agents in the drug development pipeline, such as bispecific antibodies and additional CAR T-cell therapies.
Several therapeutic agents have been recently approved by the Food and Drug Administration for the treatment of multiple myeloma. There are many novel agents in the pipeline, including bispecific antibodies and CAR T-cell therapies that have the potential to continue to change the treatment landscape of multiple myeloma.
总结新型和新兴疗法治疗多发性骨髓瘤的药理学、疗效、安全性和剂量/给药。
近年来，多发性骨髓瘤的治疗取得了重大进展，可用的药物治疗方法也有所增加。多发性骨髓瘤的新疗法包括抗 CD38 单克隆抗体达雷妥尤单抗和伊沙妥昔单抗、核输出蛋白 1 抑制剂塞利尼索、抗 B 细胞成熟抗原（BCMA）抗体-药物偶联物贝兰他单抗马妥珠单抗和嵌合抗原受体（CAR）T 细胞疗法 idecabtagene vicleucel。这些药物具有独特的毒性特征、特定的监测参数和操作注意事项，治疗多发性骨髓瘤的临床医生应该了解这些。由于药物开发管道中有许多新型的研究性药物，如双特异性抗体和其他 CAR T 细胞疗法，因此很可能会继续为多发性骨髓瘤患者快速扩展新的药物。
最近，美国食品和药物管理局批准了几种治疗多发性骨髓瘤的治疗药物。管道中有许多新型药物，包括双特异性抗体和 CAR T 细胞疗法，它们有可能继续改变多发性骨髓瘤的治疗格局。
